Evidence map›Paper›PMID 35372017›Full record

ArticleFrontiers in oncology2022

Development of a Risk Assessment Model for Early Grade ≥ 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter, Real-World Analysis in China.

Yufeng Shang, Weida Wang, Yuxing Liang, Natasha Mupeta Kaweme, Qian Wang, Minghui Liu, Xiaoqin Chen, Zhongjun Xia, Fuling Zhou

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Advanced disease and CD8Frontiers in immunology · 2025
    Article
  3. Review
  4. Article
  5. Eastern Cooperative Oncology Group,Frontiers in microbiology · 2023
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Yufeng ShangDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Weida WangDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yuxing LiangDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Natasha Mupeta KawemeDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Qian WangDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Minghui LiuDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Xiaoqin ChenDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhongjun XiaDepartment of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Fuling ZhouDepartment of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Wuhan University · CNZhongnan Hospital of Wuhan University · CNSun Yat-sen University · CNSun Yat-sen University Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The study aimed to assess factors associated with early infection and identify patients at high risk of developing infection in multiple myeloma. Methods: The study retrospectively analyzed patients with MM seen at two medical centers between January 2013 and June 2019. One medical center reported 745 cases, of which 540 of the cases were available for analysis and were further subdivided into training cohort and internal validation cohort. 169 cases from the other medical center served as an external validation cohort. The least absolute shrinkage and selection operator (Lasso) regression model was used for data dimension reduction, feature selection, and model building. Results: Bacteria and the respiratory tract were the most common pathogen and localization of infection, respectively. In the training cohort, PS≥2, HGB<35g/L of the lower limit of normal range, β2MG≥6.0mg/L, and GLB≥2.1 times the upper limit of normal range were identified as factors associated with early grade ≥ 3 infections by Lasso regression. An infection risk model of MM (IRMM) was established to define high-, moderate- and low-risk groups, which showed significantly different rates of infection in the training cohort (46.5% vs. 22.1% vs. 8.8%, Conclusion: In this study, we determined risk factors for early grade ≥ 3 infection and established a predictive model to help clinicians identify MM patients with high-risk infection.

Indexed as

infectioninfection modelmultiple myelomanovel drugrisk factors

Identifiers

PMID35372017
PMCPMC8967980
OpenAlexW4220893027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.